🇫🇷 France Country × Condition
systemic sclerosis Clinical Trials in France
Active clinical trials for systemic sclerosis with research sites in France. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 5 // Recruiting: 5 // Updated: Daily
Total Trials
5
Recruiting Now
5
Country
🇫🇷 France
Active Trials in France (5)
NCT04265144
Recruiting
Cohort of Patients With Systemic Sclerosis Within the Framework of the RESO Reference Centre
Enrollment
500 pts
Country
🇫🇷 France
University Hospital, Bordeaux
View Trial → NCT04334031
Recruiting
Deployment o the Multidisciplinary Prospective Cohort Imminent
Enrollment
2,200 pts
Country
🇫🇷 France
University Hospital, Lille
View Trial → NCT06051773
Recruiting
Evaluation of Muscle Involvement in Systemic Sclerosis
Enrollment
150 pts
Country
🇫🇷 France
Central Hospital, Nancy, France
View Trial → NCT05482607
Recruiting
Evaluation of HRCT Patterns in Systemic Sclerosis-associated Interstitial Lung Disease
Enrollment
100 pts
Country
🇫🇷 France
Central Hospital, Nancy, France
View Trial → NCT05532865
Recruiting
Prospective Cohort of Patients With Systemic Sclerosis at Brest University Hospital With Biobanking
Enrollment
100 pts
Country
🇫🇷 France
University Hospital, Brest
View Trial → Frequently Asked Questions
How many systemic sclerosis clinical trials are active in France?
There are currently 5 active clinical trials for systemic sclerosis with sites in France, of which 5 are actively recruiting patients.
How can I join a systemic sclerosis clinical trial in France?
To join a systemic sclerosis clinical trial in France, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in France directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are systemic sclerosis trials in France?
Active systemic sclerosis trials in France span multiple phases. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.